QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent

QIAGEN announced that the German Federal Patent Court has ruled in its favor in a patent dispute against SD Biosensor, reaffirming the validity of an important patent protecting key innovations in its QuantiFERON technology.

The court’s decision upholds QIAGEN’s intellectual property rights involving the German part of European Patent EP 3 421 997, which protects key innovations in tuberculosis detection. Patents covering these innovations have been issued to QIAGEN in several other countries, and form part of a group of more than 120 patents currently issued for QuantiFERON.

QIAGEN release